J&J’s 55-Day Approval, Atavistik’s $160M Raise, TrumpRx Stalls

Johnson & Johnson’s teclistamab combination secured a record-breaking 55-day FDA approval under the Commissioner’s National Priority Voucher pilot, setting a new benchmark for accelerated hematology reviews. Meanwhile, the strategic onshoring thesis gains momentum as Atavistik Bio closes a $40 million Series B extension (bringing total proceeds to $160 million) for allosteric blood disorder therapies. CVS Health and Google Cloud unveiled Health100, an AI-native consumer engagement platform, while the administration’s TrumpRx portal faces early headwinds one month post-launch with daily searches dropping to approximately 11,000 from a February 6 high of 569,000.

Top Story: FDA Approves J&J’s Tec-Dara Combo in Record 55 Days

What Happened: The FDA granted approval to Johnson & Johnson’s Tec-Dara (teclistamab plus daratumumab hyaluronidase-fihj) for relapsed/refractory multiple myeloma in adults who have received at least one prior line of therapy.

The Record Timeline:

This marks the third approval under the Commissioner’s National Priority Voucher (CNPV) pilot program:

1. Zongertinib (Boehringer Ingelheim): 44 days (HER2-mutant NSCLC)
2. [Second approval not specified in email]
3. Tec-Dara (J&J): 55 days (multiple myeloma)

Clinical Results:

Phase 3 MajesTEC-3 trial demonstrated:

• 83% reduction in risk of disease progression or death (HR 0.17; p<0.0001) vs. standard physician-choice regimens
• 36-month progression-free survival rate: 83.4% vs. 29.7% for standard of care

Multiple Myeloma Background:

Multiple myeloma is blood cancer characterized by:

• Malignant plasma cell proliferation in bone marrow
• Bone destruction, anemia, kidney damage
• Approximately 35,000 new U.S. cases annually
• Median survival improving with new therapies but remains incurable

Treatment Landscape:

First-line therapy:

• Proteasome inhibitors (bortezomib)
• Immunomodulatory drugs (lenalidomide, pomalidomide)
• Monoclonal antibodies (daratumumab)
• Triple therapy combinations

Relapsed/refractory setting:

• Disease eventually develops resistance to initial treatments
• Multiple sequential therapies required
• Each line of therapy progressively less effective
• Critical need for novel mechanisms

Teclistamab Mechanism:

Teclistamab is a bispecific antibody that:

• Binds BCMA (B-cell maturation antigen) on myeloma cells
• Binds CD3 on T cells
• Brings T cells into contact with cancer cells
• Activates T cells to kill myeloma cells

Daratumumab Background:

Daratumumab (Darzalex) is established anti-CD38 monoclonal antibody that:

• Kills myeloma cells through multiple mechanisms
• Widely used in myeloma treatment
• Proven safety and efficacy profile

The Combination Rationale:

Combining bispecific T-cell engager with anti-CD38 antibody provides:

• Dual mechanism attack on myeloma cells
• Complementary pathways (T-cell engagement + antibody-mediated killing)
• Potentially deeper, more durable responses

What Makes This Historic:

Earliest bispecific indication: This represents the earliest indication for a bispecific antibody in multiple myeloma—second-line setting (after only one prior therapy) vs. third-line or later for other bispecifics.

Traditional approval pathway: J&J successfully converted teclistamab monotherapy from accelerated to traditional approval while simultaneously securing combo indication, demonstrating regulatory execution.

Unprecedented efficacy: 83% risk reduction is exceptional in multiple myeloma. The 83.4% vs. 29.7% PFS rate at 36 months shows durability rarely seen in relapsed/refractory setting.

Strategic Positioning:

J&J’s “synergy-first” strategy creates competitive moat:

• Competitors must now match or exceed 83% risk reduction in randomized trials
• This is incredibly high bar requiring years to achieve
• J&J captures second-line market while competitors lag

Synergy with Darzalex Franchise:

J&J’s existing Darzalex infrastructure enables:

• Seamless commercial integration
• Established KOL relationships
• Existing payer contracts
• Manufacturing and supply chain synergies

Safety Considerations:

Bispecific antibodies can cause:

• Cytokine release syndrome (CRS): T-cell activation causing cytokine storm
• ICANS: Immune effector cell-associated neurotoxicity syndrome
• Infections: Immune system effects increasing infection risk

Risk Evaluation and Mitigation Strategy (REMS) requirements may limit administration to specialized centers with experience managing these toxicities.

Market Implications:

Peak sales potential: $3-5 billion

• Large relapsed/refractory population
• Early-line positioning captures healthier patients
• Combination with established Darzalex
• Strong efficacy data supporting adoption

Competitive Threats:

CAR-T therapies:

• Idecabtagene vicleucel (Abecma)
• Ciltacabtagene autoleucel (Carvykti)
• Moving into earlier lines

Other bispecifics:

• Elranatamab
• Talquetamab
• Various in development

Competition will intensify as CAR-T and other bispecifics pursue earlier-line indications.

What to Watch: Real-world safety and efficacy data, payer coverage decisions, administration logistics (inpatient vs. outpatient), and competitive CAR-T positioning in earlier lines.

Atavistik Bio: $160M Series B for Allosteric Therapies

What Happened: Cambridge-based Atavistik Bio closed a $40 million Series B extension from RA Capital Management, bringing total Series B proceeds to $160 million.

Therapeutic Focus:

The capital targets “allosteric” medicines for:

• Hereditary hemorrhagic telangiectasia (HHT)
• Myeloproliferative neoplasms

Allosteric Modulation Explained:

Traditional orthosteric inhibitors:

• Bind to enzyme active site (where substrate binds)
• Block enzyme activity completely
• Often hit multiple related enzymes (off-target effects)
• Can cause toxicity from lack of selectivity

Allosteric modulators:

• Bind to sites distant from active site
• Act as “dimmer switches” rather than on/off switches
• Fine-tune enzyme activity rather than blocking completely
• Can achieve isoform selectivity (targeting specific enzyme versions)

The Atavis Platform:

Atavistik’s technology finds small-molecule allosteric modulators for disease-driving enzymes like AKT1, which:

• Plays critical role in cell growth and survival
• Has multiple isoforms with different tissue distributions
• Requires selective modulation to avoid toxicity

Why Allosteric Approaches Matter:

Cleaner safety profiles:

• Partial modulation vs. complete inhibition
• Isoform selectivity reduces off-target effects
• Maintains some physiological enzyme function

Novel mechanisms:

• Access drug targets considered “undruggable” by orthosteric approaches
• Modulate enzymes where active site inhibition too toxic
• Create differentiation in crowded therapeutic areas

Target Indications:

Hereditary hemorrhagic telangiectasia (HHT):

• Genetic disorder causing abnormal blood vessels
• Leads to nosebleeds, GI bleeding, arteriovenous malformations
• No approved targeted therapies
• Estimated 1 in 5,000-8,000 prevalence

Myeloproliferative neoplasms:

• Blood cancers with overproduction of blood cells
• Includes polycythemia vera, essential thrombocythemia, myelofibrosis
• JAK inhibitors available but toxicity limits use
• Need for better-tolerated alternatives

Clinical Timeline:

Clinical trials in HHT expected in first half 2026, indicating:

• Lead program approaching clinical validation
• Platform demonstration in human proof-of-concept studies
• Potential for multiple indications from platform

The $160M Validation:

The substantial raise confirms:

• Institutional conviction in allosteric modulation approach
• Recognition of platform technology value (applicable across multiple targets)
• High-quality scientific team and data package
• Strategic onshoring thesis (U.S.-based development and manufacturing)

Investor Significance:

RA Capital Management is sophisticated healthcare investor. The extension signals:

• Strong confidence in platform and team
• Belief in near-term value inflection (clinical data)
• Validation of allosteric approach gaining institutional acceptance

What to Watch: HHT clinical trial initiation and data, additional program announcements, and whether allosteric modulation theme continues attracting capital.

CVS Health & Google Cloud: Health100 AI Platform

What Happened: CVS Health and Google Cloud announced strategic partnership to build Health100, an AI-native consumer engagement platform.

Platform Features:

• Google Cloud’s Gemini models: Large language models for natural language understanding
• BigQuery: Data analytics and processing
• Real-time, omni-channel support: Integrated across multiple touchpoints
• Future biometric wearable integration: Planned health monitoring capabilities

Strategic Positioning:

Open ecosystem approach:

• Serves consumers regardless of pharmacy, insurer, or PBM
• Not limited to CVS customers
• Platform neutrality to drive broader adoption

vs. Walled garden competitors:

• Traditional healthcare systems lock patients into proprietary platforms
• CVS betting openness drives faster user acquisition

Use Cases:

Potential applications include:

• Medication management: Reminders, adherence support, interaction checking
• Symptom assessment: AI-driven triage and guidance
• Care navigation: Finding providers, scheduling, insurance questions
• Chronic disease management: Ongoing monitoring and intervention
• Health information: Personalized education and resources

Why This Matters:

Consumer engagement challenge: Healthcare has historically struggled with consumer engagement. Most interactions are transactional (filling prescriptions, seeing doctor when sick).

AI opportunity:

• 24/7 availability
• Personalized interactions at scale
• Proactive outreach based on data patterns
• Reduced friction in healthcare navigation

CVS Assets:

• Massive customer base (CVS Pharmacy, MinuteClinic, Aetna insurance)
• Rich health data across pharmacy, medical, insurance
• Physical footprint (stores, clinics)
• Trusted healthcare brand

Google Assets:

• World-class AI/ML capabilities (Gemini models)
• Cloud infrastructure and analytics (BigQuery)
• Consumer product expertise
• Technical talent

Market Context:

Multiple companies pursuing AI-enabled healthcare platforms:

• Amazon (acquisition of One Medical, pharmacy business)
• Apple (Health app, monitoring devices)
• Microsoft (partnerships with healthcare systems)
• Telehealth companies (integration of AI triage)

CVS/Google partnership combines healthcare operational expertise with technology leadership.

Challenges:

• Privacy and security: Health data sensitivity requires rigorous protection
• Regulatory compliance: HIPAA and other healthcare regulations
• Clinical accuracy: AI recommendations must be medically sound
• User adoption: Consumers must trust and use platform
• Integration complexity: Connecting disparate health data sources

What to Watch: Platform launch timeline, feature set, user adoption metrics, and competitive responses from Amazon, Apple, others.

TrumpRx Reality Check: Adoption Headwinds

What Happened: One month after launch, third-party data shows TrumpRx platform facing significant adoption challenges:

• Daily searches: Dropped to approximately 11,000 from February 6 high of 569,000
• Drug availability: Currently lists only 44 drugs
• Official statistics: Administration has not released usage data

Critiques:

• Limited drug availability: 44 drugs insufficient to address broad prescription needs
• Lack of “lowest price” transparency: Platform doesn’t consistently show actual lowest available prices
• User experience issues: Navigation and functionality complaints

Background:

TrumpRx was announced in State of the Union as administration’s solution to high prescription drug costs, allowing consumers to:

• Compare prices across pharmacies
• Find lowest-cost options
• Access negotiated prices

Why This Matters:

The platform was positioned as major healthcare policy initiative. Early adoption struggles suggest:

• Implementation challenges exceed expectations
• Consumer interest waning after initial curiosity
• Limited drug coverage undermines value proposition
• Political messaging exceeds operational reality

What Would Success Require:

• Comprehensive drug coverage: Thousands of medications, not 44
• Accurate, real-time pricing: True lowest prices including all discounts
• Simple user experience: Easy comparison and navigation
• Seamless integration: Connection to pharmacy benefit managers, insurance
• Marketing and education: Sustained awareness campaign

What to Watch: Whether administration expands drug coverage, releases official statistics, or pivots strategy.

Oncology & Rare Disease Updates

Galderma: Nemluvio Peak Sales Doubled to >$4B

What Happened: Galderma doubled peak sales guidance for Nemluvio (nemolizumab) from >$2 billion to >$4 billion globally, citing stronger-than-anticipated first year in U.S. and EU.

2025 Performance:

Reported $452 million in sales, demonstrating rapid uptake.

Indications:

• Prurigo nodularis: Chronic skin condition with intense itching and nodules
• Atopic dermatitis: Inflammatory skin disease with eczema, itching

Nemolizumab Mechanism:

Anti-IL-31 receptor A antibody that blocks interleukin-31 signaling, which drives itch sensation.

Market Context:

Prurigo nodularis and atopic dermatitis represent large markets with:

• Significant unmet need in severe cases
• Limited effective therapies for itch
• Patients desperate for relief from chronic, intense pruritus

Why Guidance Doubled:

• Faster physician adoption than modeled
• Higher patient persistence on therapy
• Broader label indications than initially expected
• International market opportunities exceeding projections

Oncolytics Biotech: REO 033 Trial Launch

Launched Phase 2 randomized trial evaluating pelareorep in second-line RAS-mutated metastatic colorectal cancer.

Trial Design:

• Enrollment: 60 patients
• Randomization: Pelareorep plus bevacizumab/FOLFIRI vs. standard of care
• Data timing: Preliminary results expected by year-end

Pelareorep:

Reovirus-based oncolytic immunotherapy that:

• Selectively replicates in cancer cells with RAS pathway mutations
• Kills cancer cells through direct lysis
• Activates immune system against tumor

RAS-Mutant CRC:

Approximately 50% of colorectal cancers have RAS mutations (KRAS, NRAS), creating:

• Resistance to EGFR-targeted therapies
• Limited targeted treatment options
• High unmet need for effective therapies

Clinical & Research Updates

Vertex: JOURNAVX Opioid-Free Pain Data

What Happened: Vertex presented Phase 4 data for suzetrigine (brand name JOURNAVX) in post-surgical pain management following plastic surgery.

Results:

• 90.9% of patients remained opioid-free through 14 days post-surgery with suzetrigine as part of multimodal treatment
• 90.7% rated pain control as excellent, very good, or good

Suzetrigine Mechanism:

Selective NaV1.8 sodium channel blocker that:

• Targets pain-specific sodium channel
• Avoids CNS effects of opioids
• Provides analgesia without addiction risk

Market Opportunity:

Plastic surgery context:

• Millions of procedures annually (cosmetic, reconstructive)
• Post-operative pain management critical
• Patient preference for non-opioid options
• Cash-pay procedures may accept premium pricing

Broader pain market:

• Opioid epidemic drives demand for alternatives
• Non-opioid mechanisms highly valued
• Potential expansion to other surgical types
• Acute and chronic pain indications possible

Commercial Challenges:

• Payer resistance: Will insurance cover premium non-opioid vs. cheap generic alternatives (naproxen, gabapentin)?
• Price sensitivity: How much premium over generics will market accept?
• Clinical adoption: Will surgeons change discharge protocols?

Success Scenarios:

Base case: JOURNAVX becomes standard discharge protocol for aesthetic and reconstructive surgeries, achieving blockbuster status by 2027, validating Vertex’s non-opioid pain franchise beyond cystic fibrosis.

Downside: Severe payer reluctance limits uptake to high-end, cash-pay private clinics, capping commercial trajectory.

Gilead: Yeztugo “One2PrEP” Campaign

What Happened: Gilead continues “One2PrEP” consumer campaign for Yeztugo, its twice-yearly HIV pre-exposure prophylaxis medication, featuring reimagined version of Ciara’s “1, 2 Step.”

Market Context:

• Daily oral PrEP: Truvada, Descovy (Gilead), generic options
• Long-acting injectable: Cabenuva (ViiV), Yeztugo (Gilead)

The Shift:

From daily pills to long-acting injectables offering:

• Improved adherence (no daily pills to remember)
• Privacy (no visible medication)
• Better efficacy in adherence-challenged populations
• Reduced stigma

Gilead Projection:

$800 million in 2026 Yeztugo sales, indicating:

• Significant market uptake expected
• Shift from daily oral to injectable gaining momentum
• Substantial commercial investment supporting launch

Policy & Public Health

340B Data Collection Dispute

What Happened: Hospital groups lobbying HRSA (Health Resources and Services Administration) to block expanded claims-data collection policies from Eli Lilly and Novo Nordisk.

The Issue:

Lilly and Novo requiring comprehensive claims-level data to prevent duplicate discounts under 340B program.

340B Background:

Federal program requiring pharmaceutical manufacturers to provide discounts to:

• Safety-net hospitals
• Federally qualified health centers
• Other eligible entities serving low-income populations

Manufacturer Concern:

Duplicate discounts when:

• Drug dispensed under 340B pricing
• Also subject to Medicaid rebate
• Manufacturers paying twice for same prescription

Hospital Concern:

Claims-data requirements create:

• Substantial administrative burden
• Software and compliance costs
• Potential for enrollment in program to become economically unfeasible

March 3 AHA Letter:

American Hospital Association urged HRSA to:

• Take immediate enforcement action
• Impose civil monetary penalties against Lilly and Novo
• Block expanded data collection requirements

The Escalation:

Expect additional manufacturers to follow Lilly/Novo precedent, potentially forcing difficult choices about:

• 340B program participation
• Program restructuring
• Administrative cost absorption

FDA Opioid Disposal Initiative

What Happened: FDA issued Request for Information seeking public comment on new standards for in-home opioid disposal products.

Commissioner Makary Statement:

“Having unused opioids laying around at home can be a significant risk… and a gateway for opioid-naïve family members.”

The Problem:

• Leftover prescription opioids in medicine cabinets
• Access by family members, visitors, children
• Diversion for non-medical use
• Overdose risk

Disposal Options:

Current approaches:

• Take-back programs (DEA-sponsored events)
• Pharmacy drop boxes
• Flushing certain medications
• Household trash (with precautions)

Proposed standards: FDA seeking input on in-home disposal products that:

• Safely deactivate or destroy opioids
• Prevent retrieval from trash
• Simple for patients to use
• Affordable and accessible

Policy Context:

Part of broader opioid crisis response addressing:

• Overprescribing
• Diversion
• Access by unauthorized users
• Environmental contamination from disposal

Strategic Themes

The CNPV Competitive Advantage

Three approvals under Commissioner’s National Priority Voucher pilot (44 days, 55 days) demonstrate:

• Massive time-to-market advantage for qualifying products
• 9-12 months additional patent-protected revenue
• First-mover positioning in competitive markets

What qualifies:

• Breakthrough designation
• Critical unmet need
• Domestic manufacturing commitment
• Strong efficacy evidence

Mid-cap oncology players should pursue aggressive U.S. manufacturing strategies to access this pathway.

The Allosteric Modulation Shift

Atavistik’s $160M raise confirms institutional conviction that allosteric modulation offers:

• Cleaner safety profiles than orthosteric inhibitors
• Isoform selectivity achieving targeted effects
• Access to “undruggable” targets

Structural pivot away from traditional active-site inhibitors gaining momentum.

Health Tech Platform Race

CVS/Google Health100 positions against Amazon, Apple, Microsoft in AI-enabled healthcare platforms. Open ecosystem approach vs. walled gardens will test whether neutrality drives faster adoption.

Frequently Asked Questions

Q: How significant is 83% risk reduction in multiple myeloma?

Exceptional. The 83.4% vs. 29.7% progression-free survival rate at 36 months is unprecedented in relapsed/refractory setting. This creates massive competitive moat—competitors must match or exceed this efficacy in randomized trials, requiring years. J&J captures second-line market while others lag.

Q: What makes allosteric modulators better than traditional inhibitors?

Act as “dimmer switches” rather than on/off switches, partially modulating enzyme activity vs. complete blockade. Achieve isoform selectivity targeting specific enzyme versions without hitting related enzymes, resulting in cleaner safety profiles. Can modulate targets where active-site inhibition too toxic.

Q: Why is TrumpRx struggling?

Only 44 drugs listed (insufficient coverage), daily searches dropped 98% from peak (11,000 vs. 569,000), lacks true “lowest price” transparency, poor user experience. Platform overpromised and underdelivered—political messaging exceeded operational capability. Needs comprehensive drug coverage and accurate pricing to be useful.

Q: Can Vertex’s JOURNAVX compete with generic pain medications?

Depends on payer coverage. Clinical data compelling (90.9% opioid-free, 90.7% satisfied with pain control), but generics cost pennies vs. premium pricing for novel mechanism. If payers cover in context of opioid epidemic, could achieve blockbuster status. If resistance forces cash-pay only, limited to high-end private practices.

Q: What is Health100 and why does CVS/Google partnership matter?

AI-native consumer health platform using Google’s Gemini models and data analytics. Open ecosystem serving anyone regardless of pharmacy/insurer vs. traditional walled gardens. Combines CVS’s healthcare operational expertise/customer base with Google’s AI/technology leadership. Tests whether platform neutrality drives adoption faster than proprietary systems.

Q: Why are hospitals fighting 340B data requirements?

Lilly and Novo demanding comprehensive claims-level data to prevent duplicate discounts creates substantial administrative burden and software costs for hospitals. If many manufacturers follow suit, compliance costs may exceed 340B program benefits, forcing hospitals to exit program meant to support safety-net care for low-income populations.

Q: Is Galderma’s >$4B peak sales realistic for Nemluvio?

Achieving $452M in first year with guidance doubling from >$2B to >$4B suggests yes. Prurigo nodularis and atopic dermatitis represent large markets with intense unmet need for itch control. Anti-IL-31 mechanism addresses this directly. Strong first-year performance indicates faster adoption and higher persistence than initially modeled.

Q: What does J&J’s 55-day approval mean for competitors?

Creates massive time disadvantage. J&J gets 9-12 additional months of market exclusivity before competitors can launch, capturing second-line multiple myeloma market share. Competitors must pursue domestic manufacturing and CNPV qualification or accept permanent lag in competitive positioning.

About BioMed Nexus

BioMed Nexus provides daily intelligence for leaders in biotech, medtech, and pharma.

Get the daily brief delivered before market open — Subscribe at biomednexus.com

Pro members access institutional analysis including scenario modeling, competitive positioning frameworks, and probability-weighted outcomes.

Explore Pro Membership →

This analysis is for informational purposes and does not constitute investment advice. All information verified as of March 6, 2026.